1. Hemodiafiltration for hepatic encephalopathy induced by Budd–Chiari syndrome in a patient with end-stage kidney disease
- Author
-
Suguru Yamamoto, Takeshi Nakatsue, Junichiro James Kazama, Yoshikatsu Kaneko, Ichiei Narita, Noriaki Iino, Seitaro Iguchi, Takuya Wakamatsu, Kenya Kamimura, and Shin Goto
- Subjects
Nephrology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,030232 urology & nephrology ,Renal function ,Case Report ,General Medicine ,medicine.disease ,Gastroenterology ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Antiphospholipid syndrome ,Internal medicine ,Budd–Chiari syndrome ,Medicine ,030211 gastroenterology & hepatology ,Hemodialysis ,business ,Hepatic encephalopathy ,Dialysis ,Kidney disease - Abstract
A 36-year-old woman who was undergoing dialysis for end-stage kidney disease (ESKD) was admitted to our hospital with consciousness disorder. She was diagnosed with Budd-Chiari syndrome due to antiphospholipid syndrome at the age of 28 years. Her kidney function and leg edema gradually deteriorated. After initiation of hemodialysis (HD), transient loss of consciousness due to hepatic encephalopathy during HD treatment occurred frequently. Her kidney replacement therapy was changed to online hemodiafiltration (HDF), which dramatically improved her hepatic coma. Compared with HD, HDF contributed to the increase in Fischer's ratio and decrease in tryptophan level, which has a high protein-bound property. This case suggests that HDF may be beneficial for hepatic encephalopathy in ESKD patients by modulating the amino acid profile.
- Published
- 2015
- Full Text
- View/download PDF